Barely Significant

Excerpts

514,629 sentences

marginally significantp = 0.051.0× alphagold
in-person) was associated with a marginally significant reduction in breastfeeding initiation (B = −0.04, p = 0.05), with the confidence interval close to zero ([−0.08, −0.001]), suggesting a slight effect of telemedicine on lowering initiation rates.
a decreasing trendp < 0.051.0× alphagold
The CP content of the LAB group, CE group and LAB + CE group was increased by 17.41%, 12.02%, and 20.49%, respectively, compared to that of the CON group, and no difference was noted for the CP on the 2-way interaction of LAB × CE.The NDFom content in the LAB treatment group was not significantly different compared to the CON group( p > 0.05), and both the CE and LAB + CE groups showed a decreasing trend in DNFom content compared with the CON group, with decreases of 16.41% and 18.74%, respectively ( p < 0.05).
borderline significantp = 0.0501.0× alphagold
The 11 men who had erectile and ejaculatory dysfunction as a plausible escitalopram side-effect had lower mean testosterone (13.8 ± 4.7 nM) and estradiol (0.084 ± 0.023 nM) than the men without the side-effects (19.6 ± 8.7 nM and 0.110 ± 0.034 nM), which was borderline significant for testosterone (Hedges' g = 0.81, t (18.9) = 2.1, p = 0.050) and significant for estradiol using Welch's tests (Hedges' g = 0.86, t (20.9) = 2.2, p = 0.039).
an increasing trendp ≤ 0.051.0× alphagold
The odds ratio showed an increasing trend with longer follow-up periods (OR = 1.70; 95% CI 1.36–2.13; p ≤ 0.05 at ≤1 month, OR = 1.86; 95% CI 1.50–2.32; p ≤ 0.05 at ≤3 months, OR = 2.29; 95% CI 1.90–2.75; p ≤ 0.05 at ≤4 months, OR = 2.40; 95% CI 1.99–2.91; p ≤ 0.05 at ≤6 months, OR = 2.50; 95% CI 2.11–2.97; p ≤ 0.05 at ≤1 year).
a decreasing trendp < 0.051.0× alphagold
A similar B-cell (CD20) and fibroblast (CD90) content was present in all tissues tested ( Figure 4B e,f), while a decreasing trend for T cells (CD3) could be detected in the adalimumab scFv-Fc ( p < 0.05 and p = 0.05) and A7/adalimumab ( p = 0.1 and p = 0.05) treatment groups compared to control and E2/adalimumab ( Figure 4B c).